Logo

Ferring and Blackstone Collaborate to Establish Joint Venture Focusing on the Development of Gene Therapy for Bladder Cancer

Share this
Ferring and Blackstone Collaborate to Establish Joint Venture Focusing on the Development of Gene Therapy for Bladder Cancer

Ferring and Blackstone Collaborate to Establish Joint Venture Focusing on the Development of Gene Therapy for Bladder Cancer

Shots:

  • Ferring launches a new company FerGene focusing the global development and commercialization of Nadofaragene firadenovec in the US for the patients with Bacillus Calmette-Guérin (BCG) unresponsive- non-muscle invasive bladder cancer
  • Blackstone to invest $400M and its expertise to accelerate the future development and commercialization of Nadofaragene firadenovec while Ferring will invest up to $170M and will get MAA for the therapy if approved by the US FDA.
  • Nadofaragene firadenovec is an adenovirally mediated interferon alfa-2b gene therapy being developed in P-III study as a treatment for patients with high-grade- BCG unresponsive- NMIBC and has received FDA’s PR & BT designation. The US FDA has accepted BLA filing for Nadofaragene firadenovec

Click here to­ read full press release/ article | Ref: Blackstone | Image: VC Circle


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions